Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB held an extraordinary general meeting on 14 January 2026 in Huddinge, where shareholders approved a new four-member board without deputies and appointed Anders Hallberg as chairman, alongside the re-election of Uli Hacksell, Angelica Loskog and Anna Törner as ordinary board members until the next annual general meeting. The meeting also confirmed that previously decided board remuneration will remain unchanged, with the chairman’s fee to be allocated proportionally between the former and new chair based on time in office, and Hacksell to receive remuneration as an ordinary board member for the remainder of the term, signaling continuity in Medivir’s governance as it advances its oncology-focused pipeline.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish biopharmaceutical company focused on developing innovative cancer drugs for indications with high unmet medical need, particularly where existing therapies are limited or absent. Its lead candidate, fostroxacitabine bralpamide (fostrox), is designed to selectively target cancer cells in the liver while minimizing side effects, and the company pursues its pipeline through a mix of in-house development and partnerships. Medivir’s shares trade on Nasdaq Stockholm’s Small Cap list under the ticker MVIR.
Average Trading Volume: 1,159,234
Technical Sentiment Signal: Sell
Current Market Cap: SEK190.9M
Learn more about MVIR stock on TipRanks’ Stock Analysis page.